Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT06960460
Recruiting Not applicable

Study Evaluating the Performance and Safety in the Medium and Long Term of Global D ZygoFixU System

NCT06960460 · tracked via the Priya Life Science Italy tracker
Sponsor
Global D
Phase
Not applicable
Started
2025-04-10
Last updated
2025-07-02

Condition(s) studied

Dental Implants

Investigational drug(s) / intervention(s)

Dental implant surgery with ZygoFixU implants

Dental implant surgery with ZygoFixU implants: Adult patients who have had dental implant surgery.

Study summary

Global D has developed an zygomatic implant prosthetic system (ZygoFixU range): zygomatic implants, prosthetic parts and associated instruments. These devices have a design similar to other zygomatic implants on the market and are therefore not innovative. These non-CE marked devices are assessed during investigation 2302-G-ZYGO-C for their performance and for their short- and medium-term safety. These implants will be placed using specific instruments, by oral or cranio-maxillofacial surgeons with significant experience in the placement of zygomatic implants and trained in clinical research.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult male or female patient, * Patient whose growth and development of the maxillary bone is complete according to the investigator's judgement, * Partially or completely edentulous patient, * Patient with advanced maxillary atrophy (grades IV, V and VI according to the Cawood and Howell classification if used), * Patient requiring implant treatment with Global D zygomatic implants (placement of two or four implants), * Patient with acceptable oral opening (\>3 cm measured anteriorly), * Patient able to read, understand and answer the quality-of-life questionnaire of the investigation and able to give consent, * Patient agreeing to comply with the protocol design and to send his/her follow-up data, even in the event of a move, * Patient having signed the consent form, * In France, patient affiliated to a social security scheme. Exclusion Criteria: * Patient's state of health at enrolment: * General contraindications to implant surgery * Patient with zygomatic bone disease * Patient with untreated periodontal disease * Patient with acute or chronic infection in the implant placement area, or systemic infection, including acute or chronic maxillary sinusitis * Patient with acute or chronic inflammation in the implant placement area, or systemic inflammation, * Patient with uncontrolled diabetes (unstable blood glucose) * Patient with immunodeficiencies or using immunosuppressants * Patient who received radiation of more than +70 Gy to the head and neck region * Patient using intravenous aminobisphosphonates within 5 years prior to surgery * Patient who are smokers (\>10 cigarettes/day) or with alcohol or drug addiction * Person placed under legal protection (this includes guardianship, curatorship and legal protection). * Pregnant or breastfeeding women

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
CCOI Toulouse Toulouse France Not Yet Recruiting
Cabinet dentaire Dr HADJ Marseille France Recruiting
Université de Bologne Bologne Italie Not Yet Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06960460 on ClinicalTrials.gov ↗ ← All trials in Italy